1. Osteoclast Differentiation Is Suppressed by Increased O-GlcNAcylation Due to Thiamet G Treatment
- Author
-
Tomomi Hatanaka, Tomoharu Takeuchi, Yasuhiro Horimoto, Yoichiro Arata, Mayumi Tamura, Midori Oyama, Sachie Nakatani, and Kenji Kobata
- Subjects
musculoskeletal diseases ,0301 basic medicine ,Pharmacology ,Gene knockdown ,biology ,Activator (genetics) ,Chemistry ,Acid phosphatase ,Pharmaceutical Science ,General Medicine ,Peripheral blood mononuclear cell ,Cell biology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Downregulation and upregulation ,Osteoclast ,RANKL ,030220 oncology & carcinogenesis ,medicine ,biology.protein ,Macrophage - Abstract
Osteoclasts are the only bone-resorbing cells in organisms and understanding their differentiation mechanism is crucial for the treatment of osteoporosis. In the present study, we investigated the effect of Thiamet G, an O-GlcNAcase specific inhibitor, on osteoclastogenic differentiation. Thiamet G treatment increased global O-GlcNAcylation in murine RAW264 cells and suppressed receptor activator of nuclear factor-κB ligand (RANKL)-dependent formation in tartrate-resistant acid phosphatase (TRAP)-positive multinuclear cells, thereby suppressing the upregulation of osteoclast specific genes. Meanwhile, knockdown of O-linked N-acetylglucosamine (O-GlcNAc) transferase promoted the formation TRAP-positive multinuclear cells. Thiamet G treatment also suppressed RANKL and macrophage colony-stimulating factor (M-CSF) dependent osteoclast formation and bone-resorbing activity in mouse primary bone marrow cells and human peripheral blood mononuclear cells. These results indicate that the promotion of O-GlcNAc modification specifically suppresses osteoclast formation and its activity and suggest that chemicals affecting O-GlcNAc modification might potentially be useful in the prevention or treatment of osteoporosis in future.
- Published
- 2020
- Full Text
- View/download PDF